keyword
MENU ▼
Read by QxMD icon Read
search

Antiangiogenesis

keyword
https://www.readbyqxmd.com/read/28203191/airbag-associated-severe-blunt-eye-injury-causes-choroidal-rupture-and-retinal-hemorrhage-a-case-report
#1
Shih Hao Wang, Chen Chee Lim, Yu Ti Teng
A case of choroidal rupture caused by airbag-associated blunt eye trauma and complicated with massive subretinal hemorrhage and vitreous hemorrhage that was successfully treated with intravitreal injection of expansile gas and bevacizumab is presented. A 53-year-old man suffered from loss of vision in his right eye due to blunt eye trauma by a safety airbag after a traffic accident. On initial examination, the patient had no light perception in his right eye. Dilated ophthalmoscopy revealed massive subretinal hemorrhage with macular invasion and faint vitreous hemorrhage...
January 2017: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28202353/the-potential-clinical-promise-of-multimodality-metronomic-chemotherapy-revealed-by-preclinical-studies-of-metastatic-disease
#2
Robert S Kerbel, Yuval Shaked
We present a rationale for further clinical development and assessment of metronomic chemotherapy on the basis of unexpected results obtained in translational mouse models of cancer involving treatment of advanced metastatic disease. Historically, mouse cancer therapy models have been dominated by treating established primary tumors or early stage low volume microscopic disease. Treatment of primary tumors is also almost always the case when using genetically engineered mouse models (GEMMS) of cancer or patient-derived xenografts (PDXs)...
February 12, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28194552/a-novel-synthetic-small-molecule-yf-452-inhibits-tumor-growth-through-antiangiogenesis-by-suppressing-vegf-receptor-2-signaling
#3
Yongrui Liu, Yuan He, Feifei Yang, Xiaonan Cong, Jinhua Wang, Shihong Peng, Dan Gao, Weifang Wang, Liping Lan, Xuexiang Ying, Mingyao Liu, Yihua Chen, Zhengfang Yi
Tumor angiogenesis is characterized by abnormal vessel morphology, endowing tumor with highly hypoxia and unresponsive toward treatment. To date, mounting angiogenic factors have been discovered as therapeutic targets in antiangiogenic drug development. Among them, vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors exerts potent antiangiogenic activity in tumor therapy. Therefore, it may provide a valid strategy for cancer treatment through targeting the tumor angiogenesis via VEGFR2 pathway...
February 13, 2017: Science China. Life Sciences
https://www.readbyqxmd.com/read/28193190/enhanced-expression-of-vastatin-inhibits-angiogenesis-and-prolongs-survival-in-murine-orthotopic-glioblastoma-model
#4
Yi Li, Jun Li, Yat Ming Woo, Zan Shen, Hong Yao, Yijun Cai, Marie Chia-Mi Lin, Wai Sang Poon
BACKGROUND: Antiangiogenic therapies are considered promising for the treatment of glioblastoma (GB). The non-collagenous C-terminal globular NC1 domain of type VIII collagen a1 chain, Vastatin, is an endogenous antiangiogenic polypeptide. Sustained enhanced expression of Vastatin was shown to inhibit tumour growth and metastasis in murine hepatocellular carcinoma models. In this study, we further explored the efficacy of Vastatin in the treatment of GB xenografts. METHOD: Treatment of Vastatin was carried out using a nanopolymer gene vector PEI600-CyD-Folate (H1)...
February 13, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28176940/targeted-multidrug-delivery-system-to-overcome-chemoresistance-in-breast-cancer
#5
Yuan Tang, Fariborz Soroush, Zhaohui Tong, Mohammad F Kiani, Bin Wang
Chemotherapy has been widely used in breast cancer patients to reduce tumor size. However, most anticancer agents cannot differentiate between cancerous and normal cells, resulting in severe systemic toxicity. In addition, acquired drug resistance during the chemotherapy treatment further decreases treatment efficacy. With the proper treatment strategy, nanodrug carriers, such as liposomes/immunoliposomes, may be able to reduce undesired side effects of chemotherapy, to overcome the acquired multidrug resistance, and to further improve the treatment efficacy...
2017: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/28176910/apatinib-as-post-second-line-therapy-in-egfr-wild-type-and-alk-negative-advanced-lung-adenocarcinoma
#6
Shen-Cun Fang, Hai-Tao Zhang, Ying-Ming Zhang, Wei-Ping Xie
In the absence of a driver mutation, chemotherapy is the standard treatment option as first- and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large number of patients are suitable for post second-line therapies, the quality and quantity of the available drugs in this setting is poor. Apatinib, a small molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, is a first-generation oral antiangiogenesis drug approved in the People's Republic of China for use as a subsequent line of treatment for advanced gastric cancer...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28161597/angiogenesis-related-genes-and-thalidomide-teratogenesis-in-humans-an-approach-on-genetic-variation-and-review-of-past-in-vitro-studies
#7
Thayne Woycinck Kowalski, Lucas Rosa Fraga, Luciana Tovo-Rodrigues, Maria Teresa Vieira Sanseverino, Mara Helena Hutz, Lavínia Schuler-Faccini, Fernanda Sales Luiz Vianna
Thalidomide embryopathy (TE) has affected more than 10,000 babies worldwide. The hypothesis of antiangiogenesis as the teratogenic mechanism of thalidomide has been investigated in several experimental models; but, in humans, it has only been accessed by in vitro studies. Here, we hypothesized the effect of thalidomide upon angiogenesis-related molecules or proteins, previously identified in human embryonic cells, through the in silico STRING-tool. We also investigated ten polymorphisms in angiogenesis-related genes in 38 Brazilian TE individuals and 136 non-affected Brazilians...
February 1, 2017: Reproductive Toxicology
https://www.readbyqxmd.com/read/28122301/effects-of-js-k-a-novel-anti-cancer-nitric-oxide-prodrug-on-gene-expression-in-human-hepatoma-hep3b-cells
#8
Ray Dong, Xueqian Wang, Huan Wang, Zhengyun Liu, Jie Liu, Joseph E Saavedra
JS-K is a novel anticancer nitric oxide (NO) prodrug effective against a variety of cancer cells, including the inhibition of AM-1 hepatoma cell growth in rats. To further evaluate anticancer effects of JS-K, human hepatoma Hep3B cells were treated with JS-K and the compound control JS-43-126 at various concentrations (0-100μM) for 24h, and cytotoxicity was determined by the MTS assay. The compound control JS-43-126 was not cytotoxic to Hep3B cells at concentrations up to 100μM, while the LC50 for JS-K was about 10μM...
January 22, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28115846/preparation-of-arginine-glycine-aspartic-acid-modified-biopolymeric-nanoparticles-containing-epigalloccatechin-3-gallate-for-targeting-vascular-endothelial-cells-to-inhibit-corneal-neovascularization
#9
Che-Yi Chang, Ming-Chen Wang, Takuya Miyagawa, Zhi-Yu Chen, Feng-Huei Lin, Ko-Hua Chen, Guei-Sheung Liu, Ching-Li Tseng
Neovascularization (NV) of the cornea can disrupt visual function, causing ocular diseases, including blindness. Therefore, treatment of corneal NV has a high public health impact. Epigalloccatechin-3-gallate (EGCG), presenting antiangiogenesis effects, was chosen as an inhibitor to treat human vascular endothelial cells for corneal NV treatment. An arginine-glycine-aspartic acid (RGD) peptide-hyaluronic acid (HA)-conjugated complex coating on the gelatin/EGCG self-assembly nanoparticles (GEH-RGD NPs) was synthesized for targeting the αvβ3 integrin on human umbilical vein endothelial cells (HUVECs) in this study, and a corneal NV mouse model was used to evaluate the therapeutic effect of this nanomedicine used as eyedrops...
2017: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/28100078/percutaneous-microwave-ablation-mwa-increased-the-serum-levels-of-vegf-and-mmp-9-in-stage-i-non-small-cell-lung-cancer-nsclc
#10
Yang Ni, Xin Ye, Chao Wan, Qing Ni, Xia Yang, Guanghui Huang, Wenhong Li, Jiao Wang, Xiaoying Han, Zhigang Wei, Min Meng
BACKGROUND: Lung cancer is the leading cause of cancer death around the world. Percutaneous microwave ablation (MWA) is an emerging treatment strategy for medically inoperable early stage non-small cell lung cancer (NSCLC). In this study, we investigated the association of MWA and serum angiogensis promoters VEGF and MMP-9 in these patients subgroup. METHODS: We enrolled 52 patients with stage I NSCLC patients in this study. For each patient, blood samples were drawn by venous puncture, one immediately prior to MWA and the others on post-procedure days (PPD) 1, 3, 5, 7, 10 and 14...
January 18, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/27997164/synthesis-of-novel-c-amprgd-sunitinib-dual-conjugates-as-molecular-tools-targeting-the-%C3%AE-v%C3%AE-3-integrin-vegfr2-couple-and-impairing-tumor-associated-angiogenesis
#11
Andrea Sartori, Elisabetta Portioli, Lucia Battistini, Lido Calorini, Alberto Pupi, Federica Vacondio, Daniela Arosio, Francesca Bianchini, Franca Zanardi
On the basis of a previously discovered anti-αVβ3 integrin peptidomimetic (c(AmpRGD)) and the clinically approved antiangiogenic kinase inhibitor sunitinib, three novel dual conjugates were synthesized (compounds 1-3), featuring the covalent and robust linkage between these two active modules. In all conjugates, the ligand binding competence toward αVβ3 (using both isolated receptors and αVβ3-overexpressing endothelial progenitor EP cells) and the kinase inhibitory activity (toward both isolated kinases and EPCs) remained almost untouched and comparable to the activity of the single active units...
December 20, 2016: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/27994464/silver-nanoparticles-inhibit-the-function-of-hypoxia-inducible-factor-1-and-target-genes-insight-into-the-cytotoxicity-and-antiangiogenesis
#12
Tieshan Yang, Qian Yao, Fei Cao, Qianqian Liu, Binlei Liu, Xiu-Hong Wang
Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that is activated upon exposure to hypoxic stress. It modulates a number of cellular responses including proliferation, apoptosis, angiogenesis, and metabolism by activating a panel of target genes in response to hypoxia. The HIF-1 level is often upregulated in the hypoxic microenvironment of solid tumors, which contributes to cancer treatment failure. Here we report that silver nanoparticles (AgNPs), which are widely used as an antimicrobial agent, are an effective inhibitor of HIF-1...
2016: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/27934069/blood-brain-barrier-penetrating-albumin-nanoparticles-for-biomimetic-drug-delivery-via-albumin-binding-protein-pathways-for-antiglioma-therapy
#13
Tingting Lin, Pengfei Zhao, Yifan Jiang, Yisi Tang, Hongyue Jin, Zhenzhen Pan, Huining He, Victor C Yang, Yongzhuo Huang
Nutrient transporters have been explored for biomimetic delivery targeting the brain. The albumin-binding proteins (e.g., SPARC and gp60) are overexpressed in many tumors for transport of albumin as an amino acid and an energy source for fast-growing cancer cells. However, their application in brain delivery has rarely been investigated. In this work, SPARC and gp60 overexpression was found on glioma and tumor vessel endothelium; therefore, such pathways were explored for use in brain-targeting biomimetic delivery...
November 22, 2016: ACS Nano
https://www.readbyqxmd.com/read/27909934/current-achievements-and-future-perspectives-of-metronomic-chemotherapy
#14
REVIEW
Adriana Romiti, Rosa Falcone, Michela Roberto, Paolo Marchetti
In recent years, many anticancer drugs have been tested at metronomic dosages for a variety of tumours. Mechanisms of action attributed to metronomic chemotherapy (MCT) include antiangiogenesis, immunomodulation, direct inhibition of tumour growth, effect on tumour initiating cells and the modulation of clonal evolution. An active clinical research, aimed at testing MCT in several cancers, has been conducted over the past 15 years. However, because the majority of available results come from earlier phase II studies, mainly performed in the area of breast cancer (BC), it is clear that there are areas still to be investigated...
December 1, 2016: Investigational New Drugs
https://www.readbyqxmd.com/read/27904768/combined-vegfr-and-ctla-4-blockade-increases-the-antigen-presenting-function-of-intratumoral-dcs-and-reduces-the-suppressive-capacity-of-intratumoral-mdscs
#15
Stephanie Du Four, Sarah K Maenhout, Simone P Niclou, Kris Thielemans, Bart Neyns, Joeri L Aerts
Melanoma brain metastases (MBM) occur in 10% to 50% of melanoma patients. They are often associated with a high morbidity and despite the improvements in the treatment of advanced melanoma, including immunotherapy, patients with MBM still have a poor prognosis. Antiangiogenic treatment was shown to reduce the immunosuppressive tumor microenvironment. Therefore we investigated the effect of the combination of VEGFR- and CTLA-4 blockade on the immune cells within the tumor microenvironment. In this study we investigated the effect of the combination of axitinib, a TKI against VEGFR-1, -2 and -3, with therapeutic inhibition of CTLA-4 in subcutaneous and intracranial mouse melanoma models...
2016: American Journal of Cancer Research
https://www.readbyqxmd.com/read/27881963/angiogenesis-inhibitors-for-the-treatment-of-hepatocellular-carcinoma
#16
REVIEW
Massimiliano Berretta, Luca Rinaldi, Fabrizio Di Benedetto, Arben Lleshi, Vallì De Re, Gaetano Facchini, Paolo De Paoli, Raffaele Di Francia
Background: Angiogenesis inhibitors have become an important therapeutic approach in the treatment of hepatocellular carcinoma (HCC) patients. The therapeutic inhibition of angiogenesis of Sorafenib in increasing overall survival of patients with HCC is a fundamental element of the treatment of this disease. Considering the heterogeneous aspects of HCC and to boost therapeutic efficacy, prevail over drug resistance and lessen toxicity, adding antiangiogenic drugs to antiblastic chemotherapy (AC), radiation therapy or other targeted drugs have been evaluated...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27797175/liposome-based-systemic-glioma-targeted-drug-delivery-enabled-by-all-d-peptides
#17
Man Ying, Changyou Zhan, Songli Wang, Bingxin Yao, Xuefeng Hu, Xianfei Song, Mingfei Zhang, Xiaoli Wei, Yan Xiong, Weiyue Lu
As the most aggressive brain tumor, chemotherapy of malignant glioma remains to be extremely challenging in clinic. The blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB) are physiological and pathological barriers preventing therapeutic drugs from reaching the glioma region. In addition, vasculogenic mimicry (VM) formed by invasive glioma cells instead of endothelial cells and angiogenesis are very common in glioma, leading to the poor prognosis and recurrence of glioma. An ideal drug delivery system for glioma chemotherapy needs to traverse the BBB and BBTB and then target VM, angiogenesis, and glioma cells...
November 9, 2016: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/27794222/neovasculature-and-circulating-tumor-cells-dual-targeting-nanoparticles-for-the-treatment-of-the-highly-invasive-breast-cancer
#18
Jianhui Yao, Jingxian Feng, Xiaoling Gao, Dan Wei, Ting Kang, Qianqian Zhu, Tianze Jiang, Xunbin Wei, Jun Chen
Antiangiogenesis therapy has been served as a potent cancer treatment strategy for decades, yet disrupting neovasculature would provoke tumor cells into invasive growth and result in distal metastasis. The basic cause of cancer metastasis can be traced down to the presence of circulating tumor cells (CTCs) which detach from primary tumor site and act as 'seeds'. Epithelial cell adhesion molecule (EpCAM) is a potential biomarker for selective capture of epithelium-derived CTCs. Here, we integrated tumor neovessles-targetable ligands K237 peptide with Ep23 aptamer against EpCAM into a single drug-loaded nanoplatform using paclitaxel (PTX) as the model drug, aiming at damaging the primary tumor and neutralizing CTCs simultaneously to achieve a synergistic anti-tumor therapeutic effect...
October 22, 2016: Biomaterials
https://www.readbyqxmd.com/read/27777972/improving-vascular-maturation-using-noncoding-rnas-increases-antitumor-effect-of-chemotherapy
#19
Lingegowda S Mangala, Hongyu Wang, Dahai Jiang, Sherry Y Wu, Anoma Somasunderam, David E Volk, Ganesh L R Lokesh, Xin Li, Sunila Pradeep, Xianbin Yang, Monika Haemmerle, Cristian Rodriguez-Aguayo, Archana S Nagaraja, Rajesha Rupaimoole, Emine Bayraktar, Recep Bayraktar, Li Li, Takemi Tanaka, Wei Hu, Cristina Ivan, Kshipra M Gharpure, Michael H McGuire, Varatharasa Thiviyanathan, Xinna Zhang, Sourindra N Maiti, Nataliya Bulayeva, Hyun-Jin Choi, Piotr L Dorniak, Laurence J N Cooper, Kevin P Rosenblatt, Gabriel Lopez-Berestein, David G Gorenstein, Anil K Sood
Current antiangiogenesis therapy relies on inhibiting newly developed immature tumor blood vessels and starving tumor cells. This strategy has shown transient and modest efficacy. Here, we report a better approach to target cancer-associated endothelial cells (ECs), reverse permeability and leakiness of tumor blood vessels, and improve delivery of chemotherapeutic agents to the tumor. First, we identified deregulated microRNAs (miRs) from patient-derived cancer-associated ECs. Silencing these miRs led to decreased vascular permeability and increased maturation of blood vessels...
October 20, 2016: JCI Insight
https://www.readbyqxmd.com/read/27768975/anti-angiogenesis-through-noninvasive-to-minimally-invasive-intraocular-delivery-of-the-peptide-cc12-identified-by-in%C3%A2-vivo-directed-evolution
#20
Chong Chen, Kun Liu, Yupeng Xu, Pengwei Zhang, Yan Suo, Yi Lu, Wenyuan Zhang, Li Su, Qing Gu, Huamao Wang, Jianren Gu, Zonghai Li, Xun Xu
Anti-vascular endothelial growth factor (VEGF) therapies are widely used for the treatment of neovascular fundus diseases such as diabetic retinopathy. However, these agents need to be injected intravitreally, because their strong hydrophilicity and high molecular weight prevent them from penetrating cell membranes and complex tissue barriers. Moreover, the repeated injections that are required can cause infection and tissue injury. In this study, we used in vivo-directed evolution phage display technology to identify a novel dodecapeptide, named CC12, with the ability to penetrate the ocular barrier in a noninvasive (via conjunctival sac instillation) or minimally invasive (via retrobulbar injection) manner...
September 30, 2016: Biomaterials
keyword
keyword
33576
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"